In August, the Department of Health and Social Care (DHSC) asked pharmaceutical companies to hold a minimum of six weeks extra of supply of medicines 'over and above their business as usual operational buffer stock' in the event of a no-deal Brexit.
While some people welcomed the initiative, others argued that more needs to be done to safeguard products access and patient safety given the uncertainty around the availability of medicines post-Brexit.
The Pharmacist’s reporter Léa Legraien spoke to four pharmacy experts about how the Government's stockpiling plans could affect the sector. Listen to the podcast below to find out what they had to say.
For more on how community pharmacy could be affected by Brexit, see here.
What do you think? Tweet us your views @Pharmacist_News
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.